Zinc finger protein 555 (ZNF555)

Zinc finger protein 555 (ZNF555) is a human protein encoded by the ZNF555 gene on chromosome 19p13.3 that functions as a putative transcription factor, likely involved in the regulation of gene transcription and expression by binding to DNA via its C2H2-type zinc finger domain[4][3][2]. ZNF555 is predominantly localized to the nucleus and may regulate the activity of target promoters, as shown by its ability to bind transcriptional activator sites in certain genomic loci, with possible implications in skeletal muscle differentiation and disease[6][9][5]. There is no established evidence that ZNF555 is a direct therapeutic target or that small-molecule drugs interact with this protein, nor is it a well-established biomarker or noted for specific therapeutic safety concerns at this time. Zinc finger protein 555 is categorized as a transcription factor of the C2H2-type zinc finger protein family, which is the largest family of transcription factors in the human genome[3][1]. ZNF555 is predicted to contribute to transcriptional regulation, particularly associated with RNA polymerase II-dependent transcription[5][3][7]. Disease associations reported include Facioscapulohumeral muscular dystrophy (FSHD1 and FSHD2, digenic), related to its binding at transcriptional activator sites relevant to muscle gene regulation[5][6][9]. No drugs or therapeutic agents have been reported to directly target ZNF555, and it is not described as an established receptor, enzyme, transporter, or signaling target for pharmacological intervention[5][9]. There are no known roles for ZNF555 as a clinically adopted biomarker or specific safety issues highlighted in the literature. If a highly specific structured model or drug targeting information is discovered in future databases or research, these fields can be updated. All facts are based on indexed gene, protein, and disease database information as of September 2025.

Other names

ZNF555MGC26707zinc finger protein 555